23
May

After an FDA rejection and an earlier negative opinion, Novartis’ cardio treatment serelaxin has again failed to sway European regulators, and the drugmaker has resigned that its breakthrough-designated therapy will not hit any market this year.

…read more

Source: The EU’s not impressed with Novartis’ ‘breakthrough’ cardio drug, either

    

0 No comments